To overcome the resistance developed in certain wild-type or mutant c-KIT-positive cancers treated with TK inhibitors such as imatinib, it has been proposed the use of mAbs to target and inhibit dysregulated c-KIT. The gene discussed is KIT; the disease is cancer.